To validate the antitumor efficacy of LNPs in another tumor type,we employed an advanced androgen-independent bone metastatic PCa patient-derivedxenograft tumor model.96,97 Similar to breast cancer cells,prostate cancer cells also express high levels of CD44 and play animportant role in the growth and metastasis of prostate cancer.98−100 The established PDX model (LAPC9) from hormone-resistant and metastaticprostate cancer, characterized by abundant CD44 expression (Figure 7a), was used to furtherstudy the tumor-suppressive effect of LNPs. This evidence concerns the gene CD44 and prostate carcinoma.